PTC Operating Income vs Total Revenue Analysis

PTCT Stock

USD 32.14 3.57 12.50%

PTC Therapeutics financial indicator trend analysis is much more than just breaking down PTC Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PTC Therapeutics is a good investment. Please check the relationship between PTC Therapeutics Operating Income and its Total Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Operating Income vs Total Revenue

Operating Income vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PTC Therapeutics Operating Income account and Total Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between PTC Therapeutics' Operating Income and Total Revenue is -0.81. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Total Revenue in the same time period over historical financial statements of PTC Therapeutics, assuming nothing else is changed. The correlation between historical values of PTC Therapeutics' Operating Income and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of PTC Therapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Operating Income i.e., PTC Therapeutics' Operating Income and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.81

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from PTC Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PTC Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Revenue

Total revenue comprises all receipts PTC Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from PTC Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.80 in 2024, despite the fact that Tax Provision is likely to grow to (82.7 M).

	2021	2022	2023	2024 (projected)
Research Development	540.7M	651.5M	666.6M	699.9M
Total Revenue	538.6M	698.8M	937.8M	984.7M

Research Development Total Revenue

PTC Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Short Term Investments	Other Current Assets	Total Liab	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		0.78	0.89	-0.25	0.81	0.66	0.77	0.92	0.65	0.67	0.38	0.92	0.78	0.86	0.84	0.27	0.0	-0.87	0.91	0.59	0.88	0.87	0.88	0.92	0.9	0.28
Other Current Liab	0.78		0.87	-0.67	0.3	0.29	0.59	0.69	0.94	0.24	0.84	0.91	0.63	0.64	0.87	-0.17	0.07	-0.92	0.53	0.11	0.56	0.9	0.63	0.68	0.94	0.21
Total Current Liabilities	0.89	0.87		-0.63	0.58	0.52	0.8	0.84	0.86	0.41	0.49	0.98	0.92	0.76	0.94	0.32	-0.09	-0.97	0.74	0.56	0.69	0.96	0.75	0.83	0.96	0.26
Total Stockholder Equity	-0.25	-0.67	-0.63		0.16	0.0	-0.24	-0.31	-0.79	0.23	-0.63	-0.61	-0.57	-0.26	-0.67	-0.01	-0.11	0.65	-0.04	-0.05	-0.01	-0.63	-0.11	-0.23	-0.61	-0.09
Other Liab	0.81	0.3	0.58	0.16		0.61	0.55	0.82	0.17	0.83	-0.18	0.6	0.62	0.64	0.52	0.58	-0.01	-0.48	0.88	0.79	0.82	0.49	0.69	0.75	0.55	0.21
Accounts Payable	0.66	0.29	0.52	0.0	0.61		0.54	0.66	0.14	0.49	0.0	0.54	0.6	0.84	0.58	0.4	0.22	-0.56	0.73	0.65	0.57	0.59	0.71	0.75	0.5	0.3
Cash	0.77	0.59	0.8	-0.24	0.55	0.54		0.62	0.59	0.45	0.17	0.73	0.78	0.67	0.64	0.44	-0.54	-0.75	0.68	0.62	0.69	0.73	0.77	0.78	0.67	0.33
Other Assets	0.92	0.69	0.84	-0.31	0.82	0.66	0.62		0.59	0.78	0.31	0.88	0.8	0.81	0.88	0.35	0.15	-0.82	0.8	0.66	0.87	0.78	0.75	0.84	0.87	0.22
Long Term Debt	0.65	0.94	0.86	-0.79	0.17	0.14	0.59	0.59		0.14	0.79	0.85	0.65	0.46	0.81	-0.09	-0.11	-0.88	0.35	0.11	0.46	0.84	0.51	0.55	0.87	0.18
Short Term Investments	0.67	0.24	0.41	0.23	0.83	0.49	0.45	0.78	0.14		-0.1	0.45	0.42	0.48	0.42	0.37	-0.07	-0.35	0.58	0.6	0.87	0.27	0.56	0.57	0.43	0.17
Other Current Assets	0.38	0.84	0.49	-0.63	-0.18	0.0	0.17	0.31	0.79	-0.1		0.57	0.18	0.34	0.58	-0.64	0.28	-0.62	0.1	-0.41	0.2	0.59	0.29	0.3	0.65	0.11
Total Liab	0.92	0.91	0.98	-0.61	0.6	0.54	0.73	0.88	0.85	0.45	0.57		0.87	0.8	0.96	0.22	0.04	-0.98	0.76	0.5	0.72	0.96	0.76	0.85	0.99	0.26
Property Plant Equipment	0.78	0.63	0.92	-0.57	0.62	0.6	0.78	0.8	0.65	0.42	0.18	0.87		0.73	0.88	0.63	-0.14	-0.86	0.71	0.8	0.61	0.85	0.66	0.76	0.81	0.21
Short Long Term Debt Total	0.86	0.64	0.76	-0.26	0.64	0.84	0.67	0.81	0.46	0.48	0.34	0.8	0.73		0.82	0.24	0.23	-0.81	0.87	0.56	0.73	0.83	0.87	0.93	0.79	0.3
Property Plant And Equipment Net	0.84	0.87	0.94	-0.67	0.52	0.58	0.64	0.88	0.81	0.42	0.58	0.96	0.88	0.82		0.22	0.18	-0.96	0.68	0.5	0.66	0.94	0.7	0.79	0.96	0.22
Current Deferred Revenue	0.27	-0.17	0.32	-0.01	0.58	0.4	0.44	0.35	-0.09	0.37	-0.64	0.22	0.63	0.24	0.22		-0.34	-0.16	0.42	0.92	0.27	0.17	0.22	0.31	0.11	0.1
Net Debt	0.0	0.07	-0.09	-0.11	-0.01	0.22	-0.54	0.15	-0.11	-0.07	0.28	0.04	-0.14	0.23	0.18	-0.34		-0.03	0.08	-0.21	-0.11	0.06	-0.06	0.01	0.11	-0.12
Retained Earnings	-0.87	-0.92	-0.97	0.65	-0.48	-0.56	-0.75	-0.82	-0.88	-0.35	-0.62	-0.98	-0.86	-0.81	-0.96	-0.16	-0.03		-0.7	-0.44	-0.67	-0.99	-0.78	-0.84	-0.97	-0.26
Non Current Assets Total	0.91	0.53	0.74	-0.04	0.88	0.73	0.68	0.8	0.35	0.58	0.1	0.76	0.71	0.87	0.68	0.42	0.08	-0.7		0.69	0.77	0.74	0.85	0.91	0.73	0.27
Non Currrent Assets Other	0.59	0.11	0.56	-0.05	0.79	0.65	0.62	0.66	0.11	0.6	-0.41	0.5	0.8	0.56	0.5	0.92	-0.21	-0.44	0.69		0.56	0.44	0.51	0.59	0.41	0.15
Cash And Short Term Investments	0.88	0.56	0.69	-0.01	0.82	0.57	0.69	0.87	0.46	0.87	0.2	0.72	0.61	0.73	0.66	0.27	-0.11	-0.67	0.77	0.56		0.61	0.86	0.85	0.7	0.22
Net Receivables	0.87	0.9	0.96	-0.63	0.49	0.59	0.73	0.78	0.84	0.27	0.59	0.96	0.85	0.83	0.94	0.17	0.06	-0.99	0.74	0.44	0.61		0.78	0.84	0.95	0.27
Common Stock Total Equity	0.88	0.63	0.75	-0.11	0.69	0.71	0.77	0.75	0.51	0.56	0.29	0.76	0.66	0.87	0.7	0.22	-0.06	-0.78	0.85	0.51	0.86	0.78		0.93	0.73	0.19
Common Stock Shares Outstanding	0.92	0.68	0.83	-0.23	0.75	0.75	0.78	0.84	0.55	0.57	0.3	0.85	0.76	0.93	0.79	0.31	0.01	-0.84	0.91	0.59	0.85	0.84	0.93		0.82	0.44
Non Current Liabilities Total	0.9	0.94	0.96	-0.61	0.55	0.5	0.67	0.87	0.87	0.43	0.65	0.99	0.81	0.79	0.96	0.11	0.11	-0.97	0.73	0.41	0.7	0.95	0.73	0.82		0.27
Other Stockholder Equity	0.28	0.21	0.26	-0.09	0.21	0.3	0.33	0.22	0.18	0.17	0.11	0.26	0.21	0.3	0.22	0.1	-0.12	-0.26	0.27	0.15	0.22	0.27	0.19	0.44	0.27

Click cells to compare fundamentals

PTC Therapeutics Account Relationship Matchups

PTC Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.6B	2.2B	1.9B	1.7B	1.9B	2.0B
Other Current Liab	197.3M	245.8M	60.8M	365.2M	580.3M	609.3M
Total Current Liabilities	235.9M	277.3M	509.3M	406.2M	603.1M	633.3M
Total Stockholder Equity	594.3M	482.0M	1.4M	(347.1M)	(818.6M)	(777.6M)
Other Liab	490.7M	1.0B	1.1B	269.5M	309.9M	263.2M
Accounts Payable	10.3M	18.7M	23.0M	27.3M	6.0M	9.9M
Cash	686.6M	208.8M	773.4M	410.7M	594.0M	623.7M
Other Assets	16.4M	60.6M	46.5M	33.4M	38.4M	40.3M
Long Term Debt	293.9M	309.1M	281.9M	571.7M	1.9B	2.0B
Short Term Investments	398.5M	894.8M	583.7M	130.9M	282.7M	281.6M
Other Current Assets	17.9M	39.5M	(126.3M)	105.7M	150.3M	157.8M
Total Liab	1.0B	1.7B	1.9B	2.1B	2.7B	2.9B
Property Plant Equipment	21.5M	33.8M	130.0M	72.6M	83.5M	87.7M
Short Long Term Debt Total	313.9M	420.4M	431.4M	703.6M	415.0M	255.9M
Property Plant And Equipment Net	21.5M	118.2M	130.0M	175.0M	179.0M	187.9M
Current Deferred Revenue	8.2M	4.2M	265.8M	1.4M	801K	761.0K
Net Debt	(372.7M)	211.6M	(341.9M)	292.9M	(179.0M)	(187.9M)
Retained Earnings	(1.2B)	(1.6B)	(2.1B)	(2.7B)	(3.3B)	(3.1B)
Non Current Assets Total	844.5M	976.5M	1.2B	1.0B	684.6M	480.6M
Non Currrent Assets Other	30.1M	60.6M	227.5M	48.6M	20.0M	33.4M
Cash And Short Term Investments	686.6M	1.1B	773.4M	410.7M	876.7M	450.9M
Net Receivables	55.5M	69.9M	110.5M	155.6M	161.0M	169.1M
Common Stock Total Equity	62K	70K	71K	72K	82.8K	45.3K
Common Stock Shares Outstanding	58.9M	66.0M	70.5M	71.7M	74.8M	49.7M
Liabilities And Stockholders Equity	1.6B	2.2B	1.9B	1.7B	1.9B	1.0B
Non Current Liabilities Total	793.6M	1.4B	1.2B	1.6B	2.1B	2.2B
Other Stockholder Equity	1.8B	2.2B	2.1B	2.3B	2.5B	2.6B
Property Plant And Equipment Gross	21.5M	118.2M	157.2M	212.4M	230.3M	241.8M
Total Current Assets	779.3M	1.2B	773.4M	693.8M	1.2B	1.3B
Accumulated Other Comprehensive Income	(10.6M)	(61.0M)	(24.3M)	4.8M	(1.3M)	(1.3M)
Short Term Debt	20M	8.7M	159.8M	12.4M	16.0M	15.2M
Common Stock	62K	70K	71K	72K	75K	48.1K
Net Tangible Assets	(198.5M)	(315.7M)	(805.7M)	(1.1B)	(1.0B)	(970.7M)
Retained Earnings Total Equity	(1.2B)	(1.6B)	(2.1B)	(2.7B)	(2.4B)	(2.3B)
Capital Surpluse	1.8B	2.2B	2.1B	2.3B	2.7B	1.6B
Inventory	19.3M	18.7M	15.9M	21.8M	30.6M	32.1M
Deferred Long Term Liab	130.9M	136.7M	137.1M	102.8M	118.3M	70.3M
Non Current Liabilities Other	368.9M	1.0B	1.0B	971.9M	141K	134.0K

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether PTC Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if PTC Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ptc Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Ptc Therapeutics Stock:

How To Invest In PTC

Details

Is PTC Stock a good investment?

Details

What is PTC Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for PTC Stock analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume

Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.37)

Revenue Per Share

12.281

Quarterly Revenue Growth

(0.05)

Return On Assets

(0.10)

Return On Equity

(77.40)

The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PTC Operating Income vs Total Revenue Analysis

Operating Income vs Total Revenue

Operating Income vs Total Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Total Revenue

PTC Therapeutics fundamental ratios Correlations

PTC Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PTC Therapeutics fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for PTC Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 0.99	Total Liab
Total Liab	+ 0.98	Total Current Liabilities
Net Receivables	+ 0.96	Total Current Liabilities
Non Current Liabilities Total	+ 0.96	Total Current Liabilities
Property Plant And Equipment Net	+ 0.96	Total Liab
Net Receivables	+ 0.96	Total Liab

Net Receivables	- 0.99	Retained Earnings
Retained Earnings	- 0.98	Total Liab
Non Current Liabilities Total	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Retained Earnings	- 0.96	Property Plant And Equipment Net
Retained Earnings	- 0.92	Other Current Liab